Atomic AI vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
Atomic AI logo

Atomic AI

EmergingLife Sciences & BioTech

AI-Driven RNA Therapeutics & Drug Discovery

Atomic AI is a San Francisco biotech using AI and structural biology to design RNA-targeting therapeutics; founded in 2021 by Raphael Townshend (AlphaFold co-contributor); raised $35M Series A in 2022;

AI VisibilityBeta
Overall Score
D35
Category Rank
#130 of 198
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
36
Gemini
33

About

Atomic AI is a biotechnology company founded in 2021 and headquartered in San Francisco, California, at the intersection of artificial intelligence and RNA biology. The company was co-founded by Raphael Townshend, a key contributor to machine learning methods for molecular structure prediction including work related to AlphaFold, reflecting the founding team's deep expertise in applying AI to three-dimensional molecular structure. Atomic AI's platform combines machine learning with structural biology to understand and predict RNA structure and RNA-protein interactions — a capability central to designing drugs that target RNA molecules rather than proteins.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#130
Category Rank
#11
85
AI Consensus
68
stable
Trend
stable
31
ChatGPT
71
36
Perplexity
68
33
Gemini
80
34
Claude
77
37
Grok
69

Key Details

Category
AI-Driven RNA Therapeutics & Drug Discovery
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.